Home Compare ABBV vs BMY
Stock Comparison · Industry comparison · Drug Manufacturers - General

AbbVie vs Bristol-Myers Squibb Company: Which Stock Looks Stronger in 2026?

Bristol-Myers Squibb Company leads structurally, with valuation as the clearest single gap between the two profiles. AbbVie still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup broadly confirms the structural lead — Bristol-Myers Squibb Company holds the more constructive position. That puts structure and market broadly in agreement — Bristol-Myers Squibb Company's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the separation is still concentrated in valuation. Bristol-Myers Squibb Company leads by 17 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. ABBV and BMY share the same industry classification.

For a similarity-based comparison, see how AbbVie and BMY each position within their functional peer groups in AssetNext.

Peer-Relative Score
ABBV
AbbVie Inc.
44
Peer-Score
Signal qualityHigh
vs
BMY
Bristol-Myers Squibb Company
61
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing shapes this comparison more than a broad operating gap.

Dimension spread: ABBV vs BMY Profitability 40 38 Stability 68 56 Valuation 19 86 Growth 62 62 ABBV BMY
Gap Ranking
#1 Valuation +67
#2 Stability +12
#3 Profitability +2
#4 Growth
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ABBV and BMY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ABBVBMY Relative valuation Structural strength

Bristol-Myers Squibb Company and AbbVie Inc. look relatively close on structure, but the price setup still leans toward Bristol-Myers Squibb Company.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Bristol-Myers Squibb Company ranks near the top of the group; AbbVie Inc. sits in the weaker half.
Stability
On stability, the edge still sits with AbbVie Inc., even though both profiles look solid.
Valuation — Dominant Gap
ABBV
19
BMY
86
Gap+67in favour of BMY

The multiple-based pricing edge comes from a forward P/E that is 3.5 turns lower.

What else supports the lead

Market confirmation also leans toward Bristol-Myers Squibb Company, which makes the lead look better backed by actual market behaviour.

What this means for the comparison

Valuation settles the comparison, while pricing and stability keep the broader setup from looking fully aligned.

Explore full peer positioning in AssetNext

Break down the ABBV vs BMY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how ABBV and BMY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.